# Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

> **NCT06364787** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** γδ T cells
- **DRUG:** Targeted drugs
- **DRUG:** PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06364787
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2026-04-26
- **Final completion:** 2026-09-26
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364787, "Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06364787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*